Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies

References

• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169(10):5538–5545.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Bellaguarda E, Hanauer S. Checkpoint Inhibitor-induced colitis. Am J Gastroenterol. 2020;115(2):202–210.
   PubMed Web of Science ®Google Scholar
• Luoma AM, Suo S, Williams HL, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655–671.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–3029.
   PubMed Web of Science ®Google Scholar
• Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6(10):e1344805.
   PubMed Web of Science ®Google Scholar
• Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol. 2017;8:1547.
   PubMed Web of Science ®Google Scholar
• Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest. 2020;130(1):51–61.
   PubMed Web of Science ®Google Scholar
• Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28(11):2860–2865.
   PubMed Web of Science ®Google Scholar
• Adler BL, Pezhouh MK, Kim A, et al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med. 2018;283(6):568–577.
   PubMed Web of Science ®Google Scholar
• Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 2017;41(5):643–654.
   PubMed Web of Science ®Google Scholar
• Paluch C, Santos AM, Anzilotti C, et al. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306.
   PubMed Web of Science ®Google Scholar
• Totsuka T, Kanai T, Nemoto Y, et al. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis. Eur J Immunol. 2008;38(5):1275–1286.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim JH, Song MY, et al. PD-1 deficiency protects experimental colitis via alteration of gut microbiota. BMB Rep. 2017;50(11):578–583.
   PubMed Web of Science ®Google Scholar
• Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171(8):4156–4163.
   PubMed Web of Science ®Google Scholar
• Song MY, Hong CP, Park SJ, et al. Protective effects of Fc-fused PD-L1 on two different animal models of colitis. Gut. 2015;64(2):260–271.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical company Lilly. Medicines in development. [cited 2021 Jan 26]. Available from: https://www.lilly.com/discovery/clinical-development-pipeline#/
   Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of health and human services, National Institutes of health National Cancer Institute. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
   Google Scholar
• Geboes K, Riddell R, Ost A, et al. A reproducible grading Scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404–409.
   PubMed Web of Science ®Google Scholar
• Ma Y, Fang W, Zhang Y, et al. KEYNOTE-032: a randomized phase I study of pembrolizumab in chinese patients with advanced non-small cell lung cancer. Oncologist. 2020;25(8):650–e1145.
   PubMed Web of Science ®Google Scholar
• Lee KW, Lee DH, Kang JH, et al. Phase I pharmacokinetic study of nivolumab in korean patients with advanced solid tumors. Oncologist. 2018;23(2):155–e17.
   PubMed Web of Science ®Google Scholar
• Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses . Eur J Immunol. 2003;33(10):2706–2716.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang L, Feng Y, et al. A Purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice. Gut. 2020;69(11):1988–1997.
   PubMed Web of Science ®Google Scholar
• Scandiuzzi L, Ghosh K, Hofmeyer KA, et al. Tissue-expressed B7-H1 critically controls intestinal inflammation. Cell Rep. 2014;6(4):625–632.
   PubMed Web of Science ®Google Scholar
• Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38(6):576–583.
   PubMed Web of Science ®Google Scholar
• Nakazawa A, Dotan I, Brimnes J, et al. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology. 2004;126(5):1347–1357.
   PubMed Web of Science ®Google Scholar
• Cassol CA, Owen D, Kendra K, et al. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics. Histopathology. 2020;77(2):240–249.
   PubMed Web of Science ®Google Scholar
• Mezache L, Magro C, Hofmeister C, et al. Modulation of PD-L1 and CD8 activity in idiopathic and infectious chronic inflammatory conditions. Appl Immunohistochem Mol Morphol. 2017;25(2):100–109.
   PubMedGoogle Scholar
• Robertson J, Haas CT, Pele LC, et al. Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep. 2016;6:26747.
   PubMed Web of Science ®Google Scholar
• Zamani MR, Aslani S, Salmaninejad A, et al. PD-1/PD-L and autoimmunity: a growing relationship . Cell Immunol. 2016;310:27–41.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118.
   PubMed Web of Science ®Google Scholar
• Laurent S, Queirolo P, Boero S, et al. The engagement of CTLA-4 on primary melanoma cell Lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med. 2013;11:108.
   PubMed Web of Science ®Google Scholar
• Lord JD, Hackman RC, Moklebust A, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci. 2010; 55(5):1396–1405.
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017;11(10):1238–1246.
   PubMed Web of Science ®Google Scholar
• Roosenboom B, Wahab PJ, Smids C, et al. Intestinal CD103 + CD4+ and CD103 + CD8+ T-cell subsets in the gut of inflammatory bowel disease patients at diagnosis and during follow-up. Inflamm Bowel Dis. 2019;25(9):1497–1509.
   PubMed Web of Science ®Google Scholar
• Smids C, Horjus Talabur Horje CS, Drylewicz J, et al. Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course. J Crohns Colitis. 2018;12(4):465–475.
   PubMed Web of Science ®Google Scholar
• Wang G, Hu P, Yang J, et al. The effects of PDL-Ig on collagen-induced arthritis. Rheumatol Int. 2011;31(4):513–519.
   PubMed Web of Science ®Google Scholar
• Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5(3):185–186.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, et al. Combination immunotherapy: a road map. J Immunother Cancer. 2017;5:16.
   PubMed Web of Science ®Google Scholar